TP53 and colorectal cancer: The key pathways involved in the therapeutic synergistic action of poziotinib and olmutinib were apoptosis, platinum drug resistance pathway, p53-dependent apoptotic pathway, EGFR tyrosine kinase resistance pathway, and colorectal cancer pathway.